Particular interest and experience in the cardiac safety evaluation of drugs for metabolic disorders. These drugs have an ultimate objective of decreasing the cardiac risk through the control of the metabolic pathways. However demonstration of the beneficial effect on clinical endpoints is not always an easy task!
Mes compétences :
Recherche clinique
Médecine
Industrie pharmaceutique
Pharmacologie
Pas de formation renseignée
Pas de contact professionnel